Skip to main content
SpringerLink
Log in

Drug Interactions with Grapefruit Juice

Extent, Probable Mechanism and Clinical Relevance

  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Concomitant intake with grapefruit juice increases the concentrations of many drugs in humans. The effect seems to be mediated mainly by suppression of the cytochrome P450 enzyme CYP3A4 in the small intestine wall. This results in a diminished first pass metabolism with higher bioavailability and increased maximal plasma concentrations of substrates of this enzyme. The effect was most pronounced in drugs with a high first pass degradation and in many cases has the clear potential to reach clinical relevance, as shown by an occasional change in drug effects or tolerability. For felodipine, nitrendipine, nisoldipine and saquinavir, the interaction was most marked with median increases of area under the curve (AUC) and/or the maximum (peak) plasma drug concentration after singledose administration (Cmax) values exceeding 70% of respective control periods. Less pronounced, but possibly relevant, concentration increases were found for nifedipine, nimodipine, verapamil, cyclosporin, midazolam, triazolam and terfenadine. This list is not complete because many drugs have not been studied yet.

The components of grapefruit juice which are the most probable causes of the interaction are psoralen derivatives, but the flavonoid naringenin may also contribute. Concomitant grapefruit juice intake does not generally decrease the variability of drug pharmacokinetic parameters. Therefore, it is recommended that patients refrain from drinking grapefruit juice when they are taking a drug that is extensively metabolised, unless a lack of interaction has already been demonstrated for that drug. It is also recommended that drugs possibly interacting with grapefruit juice should be appropriately labelled.

A place for grapefruit juice as a drug-sparing agent in treatment involving expensive medicine cannot be derived from the information currently available on grapefruit juice interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bailey DG, Spence JD, Edgar B, et al. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989 Dec; 12(6): 357–62

    PubMed  CAS  Google Scholar 

  2. Bailey DG, Arnold JM, Spence JD. Grapefruit juice and drugs. How significant is the interaction? Clin Pharmacokinet 1994 Feb; 26(2): 91–8

    Article  PubMed  CAS  Google Scholar 

  3. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993 Apr; 35(4): 431–6

    Article  PubMed  CAS  Google Scholar 

  4. Edgar B, Bailey D, Bergstrand R, et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine - and its potential clinical relevance. Eur J Clin Pharmacol 1992; 42(3): 313–7

    Article  PubMed  CAS  Google Scholar 

  5. Bailey DG, Arnold JM, Munoz C, et al. Grapefruit juice -felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993 Jun; 53(6): 637–42

    Article  PubMed  CAS  Google Scholar 

  6. Lundahl J, Regardh CG, Edgar B, et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol 1995; 49(1–2): 61–7

    PubMed  CAS  Google Scholar 

  7. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997 May 15; 99(10): 2545–53

    Article  PubMed  CAS  Google Scholar 

  8. Bailey DG, Bend JR, Arnold JM, et al. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996 Jul; 60(1): 25–33

    Article  PubMed  CAS  Google Scholar 

  9. Bailey DG, Arnold JM, Bend JR, et al. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol 1995 Aug; 40(2): 135–40

    PubMed  CAS  Google Scholar 

  10. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991 Feb 2; 337(8736): 268–9

    Article  PubMed  CAS  Google Scholar 

  11. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 1996; 51(2): 189–93

    Article  PubMed  CAS  Google Scholar 

  12. Sigusch H, Henschel L, Kraul H, et al. Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects. Pharmazie 1994 Sep; 49(9): 675–9

    PubMed  CAS  Google Scholar 

  13. Rashid TJ, Martin U, Clarke H, et al. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995 Jul; 40(1): 51–8

    Article  PubMed  CAS  Google Scholar 

  14. Sigusch H, Hippius M, Henschel L, et al. Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation. Pharmazie 1994 Jul; 49(7): 522–4

    PubMed  CAS  Google Scholar 

  15. Fuhr U, Maier A, Blume H, et al. Grapefruit juice increases oral nimodipine bioavailability [abstract]. Eur J Clin Pharmacol 1994 Aug; 47(1): A100

    Google Scholar 

  16. Bailey DG, Arnold JM, Strong HA, et al. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993 Dec; 54(6): 589–94

    Article  PubMed  CAS  Google Scholar 

  17. Bailey DG, Munoz C, Arnold JM, et al. Grapefruit juice and naringin interaction with nitrendipine. Clin Pharmacol Ther 1992 Feb; 51(2): 156

    Google Scholar 

  18. Soons PA, Vogels BA, Roosemalen MC, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991 Oct; 50(4): 394–403

    Article  PubMed  CAS  Google Scholar 

  19. Fuhr U, Harder S, Lopez-Rojas P, et al. Increase of verapamil concentrations in steady state by coadministration of grapefruit juice [abstract]. Naunyn Schmiedeberg’s Arch Pharmacol 1994 Mar; 349 Suppl: R134

    Google Scholar 

  20. Herlitz H, Edgar B, Hedner T, et al. Grapefruit juice: a possible source of variability in blood concentration of cyclosporin A [letter]. Nephrol Dial Transplant 1993; 8(4): 375

    PubMed  CAS  Google Scholar 

  21. Min DI, Ku YM, Perry PJ, et al. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation 1996 Jul 15; 62(1): 123–5

    Article  PubMed  CAS  Google Scholar 

  22. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995 Apr 15; 345(8955): 955–6

    Article  PubMed  CAS  Google Scholar 

  23. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporin after administration with grapefruit juice. Clin Pharmacol Ther 1995 May; 57(5): 485–91

    Article  PubMed  CAS  Google Scholar 

  24. Hollander AA, van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995 Mar; 57(3): 318–24

    Article  PubMed  CAS  Google Scholar 

  25. Ioannides-Demos LL, Christophidis N, Ryan P, et al. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J Rheumatol 1997 Jan; 24(1): 49–54

    PubMed  CAS  Google Scholar 

  26. Proppe DG, Hoch OD, McLean AJ, et al. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol 1995 Mar; 39(3): 337–8

    Article  PubMed  CAS  Google Scholar 

  27. Rau SE, Bend JR, Arnold MO, et al. Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther 1997 Apr; 61(4): 401–9

    Article  PubMed  CAS  Google Scholar 

  28. Honig PK, Wortham DC, Lazarev A, et al. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996 Apr; 36(4): 345–51

    PubMed  CAS  Google Scholar 

  29. Benton RE, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996 Apr; 59(4): 383–8

    Article  PubMed  CAS  Google Scholar 

  30. Maish WA, Hampton EM, Whitsett TL, et al. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. Pharmacotherapy 1996 Nov\2-Dec; 16(6): 1046–52

    PubMed  CAS  Google Scholar 

  31. Fuhr U, Maier A, Keller A, et al. Lacking effect of grapefruit juice on theophylline pharmacokinetics. Int J Clin Pharmacol Ther 1995 Jun; 33(6): 311–4

    PubMed  CAS  Google Scholar 

  32. Weber A, Jager R, Borner A, et al. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 1996 Jan; 53(1): 41–7

    Article  PubMed  CAS  Google Scholar 

  33. Schubert W, Cullberg G, Edgar B, et al. Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women. Maturitas 1994 Dec; 20(2–3): 155–63

    Article  PubMed  CAS  Google Scholar 

  34. Kupferschmidt HH, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995 Jul; 58(1): 20–8

    Article  PubMed  CAS  Google Scholar 

  35. Hukkinen SK, Varhe A, Olkkola KT, et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995 Aug; 58(2): 127–31

    Article  PubMed  CAS  Google Scholar 

  36. Min DI, Ku YM, Geraets DR, et al. Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol 1996 May; 36(5): 469–76

    PubMed  CAS  Google Scholar 

  37. Jakobsen J, Glaus L, Graf P, et al. Unmasking of the hypotensive effect of nifedipine in normotensives by addition of the angiotensin converting enzyme inhibitor benazepril. J Hypertens 1992 Sep; 10(9): 1045–51

    Article  PubMed  CAS  Google Scholar 

  38. Kunzendorf U, Brockmoller J, Jochimsen F, et al. Neurotoxicity caused by a high cyclosporine metabolite level. Transplantation 1989 Sep; 48(3): 531–2

    Article  PubMed  CAS  Google Scholar 

  39. Reynolds JEF, editor. Maritindale. The extra pharmacopoeia. 31st ed. London: Royal Pharmaceutical Society, 1996

    Google Scholar 

  40. Botstein P. Is QT interval prolongation harmful? A regulatory perspective. Am J Cardiol 1993 Aug 26; 72(6): 50B–2B

    Article  PubMed  CAS  Google Scholar 

  41. Fournier P, Pacouret G, Charbonnier B. Une nouvelle cause de torsades de pointes: association terfenadine et troleandomycine. Ann Cardiol Angeiol (Paris) 1993 May; 42(5): 249–52

    CAS  Google Scholar 

  42. Hanrahan JP, Choo PW, Carlson W, et al. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation: a retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol 1995 May; 5(3): 201–9

    Article  PubMed  CAS  Google Scholar 

  43. Spence JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther 1997 Apr; 61(4): 395–400

    Article  PubMed  CAS  Google Scholar 

  44. The lethal qualities of grapefruit juice. Marketletter 1996 Sep 9: 23

  45. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992 Sep; 52(3): 231–8

    Article  PubMed  CAS  Google Scholar 

  46. Honig PK, Wortham DC, Zamani K, et al. Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine. Eur J Clin Pharmacol 1993; 45(1): 41–6

    Article  PubMed  CAS  Google Scholar 

  47. Fuhr U, Doehmer J, Battula N, et al. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol 1992 Jan 22; 43(2): 225–35

    Article  PubMed  CAS  Google Scholar 

  48. Schubert W, Eriksson U, Edgar B, et al. Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17 beta-estradiol. Eur J Drug Metab Pharmacokinet 1995 Jul\2-Sep; 20(3): 219–24

    Article  PubMed  CAS  Google Scholar 

  49. Zhang YD, Lorenzo B, Reidenberg MM. Inhibition of 11 beta-hydroxysteroid dehydrogenase obtained from guinea pig kidney by furosemide, naringenin and some other compounds. J Steroid Biochem Mol Biol 1994 May; 49(1): 81–5

    Article  PubMed  CAS  Google Scholar 

  50. Lee YS, Lorenzo BJ, Koufis T, et al. Grapefruit juice and its flavonoids inhibit 11 beta-hydroxysteroid dehydrogenase. Clin Pharmacol Ther 1996 Jan; 59(1): 62–71

    Article  PubMed  CAS  Google Scholar 

  51. Vanakoski J, Mattila MJ, Seppala T. Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur J Clin Pharmacol 1996; 50(6): 501–8

    Article  PubMed  CAS  Google Scholar 

  52. Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995 May; 5(3): 239–44

    Article  PubMed  CAS  Google Scholar 

  53. Merkel U, Sigusch H, Hoffmann A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol 1994; 46(2): 175–7

    Article  PubMed  CAS  Google Scholar 

  54. Runkel M, Tegtmeier M, Legrum W. Metabolic and analytical interactions of grapefruit juice and 1,2- benzopyrone (coumarin) in man. Eur J Clin Pharmacol 1996; 50(3): 225–30

    Article  PubMed  CAS  Google Scholar 

  55. Oesterheld J, Kallepalli BR. Grapefruit juice and clomipramine: shifting metabolitic ratios. J Clin Psychopharmacol 1997 Feb; 17(1): 62–3

    Article  PubMed  CAS  Google Scholar 

  56. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994 Nov–Dec; 22(6): 947–55

    CAS  Google Scholar 

  57. Morris K. Grapefruit juice: the leveller of drug metabolism. Lancet 1997 May 24; 349(9064): 1524

    Article  Google Scholar 

  58. Edwards DJ, Bellevue FH III, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996 Dec; 24(12): 1287–90

    PubMed  CAS  Google Scholar 

  59. Fukuda K, Ohta T, Oshima Y, et al. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997 Oct; 7(5): 391–6

    Article  PubMed  CAS  Google Scholar 

  60. Apseloff G, Hilliard JB, Gerber N, et al. Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. Xenobiotica 1991 Nov; 21(11): 1461–71

    Article  PubMed  CAS  Google Scholar 

  61. Apseloff G, Shepard DR, Chambers MA, et al. Inhibition and induction of theophylline metabolism by 8- methoxypsoralen. In vivo study in rats and humans. Drug Metab Dispos 1990 May–Jun; 18(3): 298–303

    CAS  Google Scholar 

  62. Mays DC, Nawoot S, Hilliard JB, et al. Inhibition and induction of drug biotransformation in vivo by 8- methoxypsoralen: studies of caffeine, phenytoin and hexobarbital metabolism in the rat. J Pharmacol Exp Ther 1987 Oct; 243(1): 227–33

    PubMed  CAS  Google Scholar 

  63. Böcker RH, Guengerich FP. Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5- bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P- 450. J Med Chem 1986 Sep; 29(9): 1596–603

    Article  PubMed  Google Scholar 

  64. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997 Feb; 25(2): 256–66

    PubMed  CAS  Google Scholar 

  65. Gan LS, Moseley MA, Khosla B, et al. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 1996 Mar; 24(3): 344–9

    PubMed  CAS  Google Scholar 

  66. Jurima-Romet M, Crawford K, Cyr T, et al. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994 Nov–Dec; 22(6): 849–57

    CAS  Google Scholar 

  67. Kroemer HK, Gautier JC, Beaune P, et al. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993 Sep; 348(3): 332–7

    Article  PubMed  CAS  Google Scholar 

  68. Thummel KE, Do S, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996 May; 59(5): 491–502

    Article  PubMed  CAS  Google Scholar 

  69. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996 Apr; 59(4): 369–75

    Article  PubMed  CAS  Google Scholar 

  70. Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991 Dec 14; 338(8781): 1488–90

    Article  PubMed  CAS  Google Scholar 

  71. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997 Mar; 32(3): 194–209

    CAS  Google Scholar 

  72. Ueda CT, Williamson BJ, Dzindzio BS. Absolute quinidine bio-availability. Clin Pharmacol Ther 1976 Sep; 20(3): 260–5

    PubMed  CAS  Google Scholar 

  73. Hardman JG, Gilman AG, Limbird LE, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996

    Google Scholar 

  74. Ueng YF, Kuwabara T, Chun YJ, et al. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 1997 Jan 14; 36(2): 370–81

    Article  PubMed  CAS  Google Scholar 

  75. Ameer B, Weintraub RA, Johnson JV, et al. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther 1996 Jul; 60(1): 34–40

    Article  PubMed  CAS  Google Scholar 

  76. Fuhr U, Kummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions? Clin Pharmacol Ther 1995 Oct; 58(4): 365–73

    Article  PubMed  CAS  Google Scholar 

  77. Larkin M. Out with the jab, in with painless pills. Lancet 1997 Jun 7; 349(9066): 1676

    Article  PubMed  CAS  Google Scholar 

  78. Robinson JWL, L’Herminier ML, Claudet HGA. The effect of naringenin on the intestinal and renal transport of organic solutes. Naunyn Schmiedeberg’s Arch Pharmacol 1979; 307: 79–89

    Article  CAS  Google Scholar 

  79. Ranganna S, Govindarajan VS, Ramana KV. Citrus fruits - varieties, chemistry, technology, and quality evaluation. Part II. Chemistry, technology, and quality evaluation. A. Chemistry. Crit Rev Food Sci Nutr 1983; 18(4): 313–86

    CAS  Google Scholar 

  80. Hagen RE, Dunlap WJ, Mizelle JW, et al. A chromatographic-fluorometric method for determination of naringin, naringenin rutinoside, and related flavanone blycosides in grapefruit juice and juice sacs. Anal Biochem 1965 Sep; 12(3): 472–82

    Article  PubMed  CAS  Google Scholar 

  81. Ranganna S, Govindarajan VS, Ramana KV. Citrus fruits. Part II. Chemistry, technology, and quality evaluation. B. Technology. Crit Rev Food Sci Nutr 1983; 19(1): 1–98

    PubMed  CAS  Google Scholar 

  82. Cheng K-J, Krishnamurty HG, Jones GA, et al. Identification of products produced by the anaerobid degradation of naringin by Butyrivibrio sp. C3. Can J Microbiol 1971; 17: 129–31

    Article  PubMed  CAS  Google Scholar 

  83. Fuhr U, Hensler S, Weindel M, et al. Biotransformation of naringin to naringenin by bacteria from human feces [abstract]. Naunyn Schmiedeberg’s Arch Pharmacol 1996 Mar; 353 Suppl: R156

    Google Scholar 

  84. Green MD, Oturu ME, Tephly TR. Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metabol Dispos 1994; 22: 709–805

    Google Scholar 

  85. Miniscalco A, Lundahl J, Regardh CG, et al. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 1992 Jun; 261(3): 1195–9

    PubMed  CAS  Google Scholar 

  86. Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 1990 Dec; 11(12): 2275–9

    Article  PubMed  CAS  Google Scholar 

  87. Ghosal A, Satoh H, Thomas PE, et al. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab Dispos 1996 Sep; 24(9): 940–7

    PubMed  CAS  Google Scholar 

  88. Fuhr U, Kroemer HK, Schymanski P. Effects of naringenin and naringin on verapamil metabolism in human liver microsomes [abstract]. Naunyn-Schmiedeberg’s Arch Pharmacol 1993 Mar; 347 Suppl: R31

    Google Scholar 

  89. Merkel U. Der Einfluβ von Flavonoiden auf die Aktivität und Kinetik ausgewählter Cytochrom P450-Enzyme bei Mensch und Maus. [PhD thesis]. Halle-Wittenberg, Germany: Martin Luther Universität, 1996

    Google Scholar 

  90. Fisher JF, Nordby HE, Waiss Jr AC, et al. A new coumarin from grapefruit peel oil. Tetrahedron 1967 Jun; 23(6): 2523–8

    Article  PubMed  CAS  Google Scholar 

  91. Ha HR, Chen J, Leuenberger PM, et al. In vitro inhibition of midazolam and quinidine metabolism by flavonoids. Eur J Clin Pharmacol 1995; 48(5): 367–71

    PubMed  CAS  Google Scholar 

  92. Riov J, Goren R, Monselise SP, et al. Effect of gamma radiation on the synthesis of scopoletin and scopolin in grapefruit peel in relation to radiation damage. Radiat Res 1971 Feb; 45(2): 326–34

    Article  PubMed  CAS  Google Scholar 

  93. Tatum JH, Berry RE. Coumarins and psoralens in grapefruit peel oil. Phytochemistry 1979; 18(3): 500–2

    Article  CAS  Google Scholar 

  94. Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci 1996; 59(13): 1025–30

    Article  PubMed  CAS  Google Scholar 

  95. Fukuda K, Ohta T, Yamazoe Y. Grapefruit component interacting with rat and human P450 CYP3A: possible involvement of non-flavonoid components in drug interaction. Biol Pharm Bull 1997 May; 20(5): 560–4

    Article  PubMed  CAS  Google Scholar 

  96. Bendriss EK, Bechtel Y, Bendriss A, et al. Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis. Br J Clin Pharmacol 1996 May; 41(5): 421–4

    Article  PubMed  CAS  Google Scholar 

  97. Cai Y, Baer-Dubowska W, Ashwood-Smith M, et al. Inhibitory effects of naturally occurring coumarins on the metabolic activation of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in cultured mouse keratinocytes. Carcinogenesis 1997 Jan; 18(1): 215–22

    Article  PubMed  CAS  Google Scholar 

  98. Maenpaa J, Juvonen R, Raunio H, et al. Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochem Pharmacol 1994 Oct 7; 48(7): 1363–9

    Article  PubMed  CAS  Google Scholar 

  99. Mays DC, Camisa C, Cheney P, et al. Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. Clin Pharmacol Ther 1987 Dec; 42(6): 621–6

    Article  PubMed  CAS  Google Scholar 

  100. Mays DC, Hilliard JB, Wong DD, et al. Activation of 8-methoxypsoralen by cytochrome P-450. Enzyme kinetics of covalent binding and influence of inhibitors and inducers of drug metabolism. Biochem Pharmacol 1989 May 15; 38(10): 1647–55

    Article  PubMed  CAS  Google Scholar 

  101. Zaigler M. Charakterisierung von Inhibitoren des Cytochrom P450-Enzyms CYP1A2 beim Menschen. [MD thesis]. Frankfurt am Main, Germany: Johann Wolfgang Goethe Universität, 1996

    Google Scholar 

  102. Mays DC, Hilliard JB, Wong DD, et al. Bioactivation of 8-methoxypsoralen and irreversible inactivation of cytochrome P-450 in mouse liver microsomes: modification by monoclonal antibodies, inhibition of drug metabolism and distribution of covalent adducts. J Pharmacol Exp Ther 1990 Aug; 254(2): 720–31

    PubMed  CAS  Google Scholar 

  103. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral bioavailability of CYP3A4 substrates by grapefruit juice constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25(11): 1228–1233

    CAS  Google Scholar 

  104. Runkel M, Bourian M, Tegtmeier M, et al. The role of naringin in the interaction of drugs with juices of grapefruit juice [abstract]. Naunyn Schmiedeberg’s Arch Pharmacol 1997 Mar; 355 Suppl. 4: R123

    Google Scholar 

  105. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 1996 Oct; 96(10): 1027–39

    Article  PubMed  CAS  Google Scholar 

  106. Willett WC. Diet and health: what should we eat? Science 1994 Apr 22; 264(5158): 532–7

    Article  PubMed  CAS  Google Scholar 

  107. Cerda JJ, Robbins FL, Burgin CW, et al. The effects of grapefruit pectin on patients at risk for coronary heart disease without altering diet or lifestyle. Clin Cardiol 1988 Sep; 11(9): 589–94

    Article  PubMed  CAS  Google Scholar 

  108. So FV, Guthrie N, Chambers AF, et al. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 1996; 26(2): 167–81

    Article  PubMed  CAS  Google Scholar 

  109. Hollander AA, van der Woude FJ, Cohen AF. Effect of grapefruit juice on blood cyclosporin concentration [letter]. Lancet 1995 Jul 8; 346(8967): 123

    PubMed  CAS  Google Scholar 

  110. Johnston A, Holt DW. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995 Jul 8; 346(8967): 122–3

    Article  PubMed  CAS  Google Scholar 

  111. Majeed A, Kareem A. Effect of grapefruit juice on cyclosporine pharmacokinetics. Pediatr Nephrol 1996 Jun; 10(3): 395–6

    Article  PubMed  CAS  Google Scholar 

  112. Pisarik P. Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Arch Fam Med 1996 Jul–Aug; 5(7): 413–6

    Article  PubMed  CAS  Google Scholar 

  113. Taniguchi S, Kobayashi H, Ishii M. Treatment of psoriasis by cyclosporine and grapefruit juice [letter]. Arch Dermatol 1996 Oct; 132(10): 1249

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinische Pharmakologie, Institut für Pharmakologie der Universität zu Köln, Gleueler Straβe 24, 50931, Köln, Germany

    Uwe Fuhr

Authors
  1. Uwe Fuhr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uwe Fuhr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fuhr, U. Drug Interactions with Grapefruit Juice. Drug-Safety 18, 251–272 (1998). https://doi.org/10.2165/00002018-199818040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199818040-00002

Keywords

Search

Navigation